Regulatory News:

DEINOVE (Paris:ALDEI) (Alternext Paris : ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals by using Deinococcus bacteria as host strains, announces today that Dennis McGrew joins* the Company’s executive committee as Chief Business Officer. Dennis will be in charge of research, industrial and commercial partnerships with a particular focus on North America.

Having completed the majority of his career in the United States, Dennis McGrew has 30 years of experience in sales, marketing and business development in the chemistry and green chemistry markets. He obtained a Bachelor of Science degree in Chemical Engineering, Washington University, St. Louis, Missouri in 1983.

Since 2010, Dennis McGrew has been a business strategy consultant for multiple companies in the engineering polymer, recycle content plastics and bio-sourced chemical intermediates/plastics industries. He has served on the Board of Directors of several privately held companies contributing to their strategy and organizational development efforts. He is also a member of the Board of Directors of Deinove since May 6, 2014.

From 2009 to 2010, he served as the Executive Vice President of Business Development and Chief Business Officer for the Californian company Genomatica, specializing in the production of biobased chemicals (mainly 1,4-butanediol – BDO and butadiene). Dennis Mc Grew served as President and CEO of NatureWorks from 2006 to 2008, attracting new investors and securing capital to double the production capacity. He joined Nature Works in 2004 as Vice President and Chief Marketing Officer, leading global development of the PLA (polylactic acid) packaging Ingeo™ range, a biodegradable plastic made from corn starch.

Dennis McGrew previously served as Global commercial director for the Engineering Plastics branch at Dow Chemical and Commercial Director for Dow Automotive Europe. He joined Dow in 1983, where he successively held numerous commercial, product management, marketing and business development positions.

“I have known DEINOVE for several years now, and I have been able to envision how their technology can bring disruptive innovation within value chains of the chemical and plastics industries. My mission is to convince industry players to step into this technological disruption that can bring them a true long-term competitive advantage,” states Dennis McGrew.

“We are quite enthusiastic to welcome Dennis within our Executive Committee,” adds Emmanuel Petiot, CEO of DEINOVE. “He has a substantial background and network in our industry and he also knows perfectly about DEINOVE, which is invaluable to us”.

* subject to and from the date of approval of his appointment by the Board of Directors

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria’s unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro‐factories" to produce high value‐added products from non‐food biomass. The Company’s primary markets are 2nd‐generation biofuels (DEINOL) and bio‐based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.

Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs almost 50 people in its new offices and laboratories located in Montpellier, France.

More information at www.deinove.com